Edwards Lifesciences (EW) PT Raised to $140 at Cowen; Named Best 2022 Idea

Cowen analyst Joshua Jennings raised the price target on Edwards Lifesciences (NYSE: EW) to $140.00 (from $125.00) while maintaining an Outperform rating and named the stock a Best Idea for 2022.

The analyst commented, "EW's investor day featured favorable business updates, a reiteration of '21 guidance (implies 4Q is tracking within range), & solid '22 guidance ranges. Mgmt’s WW TAVR growth target of 12-15% should be viewed positively. EW's TAVR franchise will benefit from multiple growth drivers, while the TMTT unit will be bolstered by U.S. Pascal approval in late ’22. Reiterate Outperform, raise PT to $140."

You May Also Be Interested In

• Edwards Lifesciences (EW) Upgraded to Buy at Deutsche Bank
• TD Cowen Reiterates Buy Rating on Netflix (NFLX)
• Weatherford International plc (WFRD) PT Raised to $144 at Goldman Sachs